Daiichi Sankyo And ArQule Expand Collaboration On Heels Of Positive ARQ 197 News

TOKYO - Daiichi Sankyo and ArQule announced a flurry of activity surrounding their oncology collaboration, including regulatory and clinical updates for c-Met inhibitor ARQ 197 and expansion of their drug discovery program based on ArQule kinase inhibitor platform (AKIP) technology